Participants were observed for two seasons, from August 31, 2021, to December 18, 2023, to evaluate vaccine efficacy, its safety and the increase in antibody levels against RSV-A and RSV-B variants.

A major breakthrough for RSV research was the discovery of a conformational change of the fusion (F) protein following the establishment of infection. The RSV F protein is a trimer in two ...

Learn to recognize dangerous RSV symptoms in children beyond typical cold signs, including breathing changes, distinctive ...

When little Eva Valdimarsdottir was just 14-months-old she was hospitalised with a severe and “very scary” case of RSV, but ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

RESVIA ®is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 /Moderna, Inc.

Specifically Cormier studies that lasting impacts and immune response of Respiratory Syncytial Virus. RSV is an infection of the lungs that is responsible for the hospitalization of 58,000 to ...